Natura &Co Holding completes corporate simplification in 2025

Natura &Co Holding S.A. held its Q4 2025 earnings call on March 17, 2026. CEO João Paulo Brotto Ferreira described 2025 as a watershed year, marked by the completion of a corporate simplification cycle started in 2022.

Natura &Co Holding S.A. (NTCOY), which now trades under the ticker NATU3 following a reverse merger, conducted its Q4 2025 earnings call on March 17, 2026, at 8:00 AM EDT. The call featured João Paulo Brotto Ferreira, CEO of Latin America and member of the executive board, and Silvia Lopes Vilas Magalhaes, CFO and IR officer. Analysts from firms including XP Investimentos, JPMorgan Chase, Itaú Corretora, Morgan Stanley, Citigroup, and Goldman Sachs participated via conference call. A slide deck was posted to the company's IR website beforehand. In his opening remarks, Ferreira stated: '2025 was a watershed year for the company as we finally wrapped up the corporate simplification cycle we kicked off back in 2022 and led by Fabio Barbosa.' He highlighted key achievements, including the divestiture of Avon International, Avon CARD, and Avon Russia over the past year. The company also streamlined its holding structure through the reverse merger, restoring trading under NATU3. Operationally, Natura &Co completed Wave 2 integration in Mexico and Argentina. Ferreira concluded: 'As a consequence, the company is back to basics, with a laser focus on our core Latin American operations.' The call emphasized a return to core operations after these restructuring efforts.

Relaterede artikler

Nuvation Bio Inc. conducted its first quarter 2026 earnings call on May 4, 2026. The company reviewed financial results for the period ending March 31, 2026, and provided a business update. Executives including CEO David Hung participated in the discussion.

Rapporteret af AI

Wacoal Holdings Corp released a slide deck for its 2026 Q4 earnings call on May 24. The materials were issued alongside the quarterly results discussion.

Ecopetrol will report on its operations, revenues, and EBITDA for the first quarter of 2026 on May 12 and 13. Interim president Juan Carlos Hurtado will present the figures instead of Ricardo Roa, who requested vacation and unpaid leave. The company projects declines in revenues and net profit compared to last year.

Rapporteret af AI

Aytu BioPharma conducted its earnings call for the fiscal 2026 third quarter on May 13, 2026. Executives discussed operational and financial results for the period ended March 31, 2026.

 

 

 

Dette websted bruger cookies

Vi bruger cookies til analyse for at forbedre vores side. Læs vores privatlivspolitik for mere information.
Afvis